• US$2,054,651 non-dilutive grant from the US National Cancer Institute to complete manufacturing of Bria-Pros+^TM clinical supply and support Phase 1/2a trial in metastatic prostate cancer
• Expands Bria-OTS+ novel personalized off-the-shelf immunotherapy platform to prostate cancer, an urgent unmet medical need
• Principal Investigator: Dr. William Oh, MD, Yale Cancer Center

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the National Cancer Institute (NCI), the United States federal government’s principal agency for cancer research and training, has awarded the Company a research grant of $2,054,651 to advance Bria-PROS+, BriaCell’s next generation personalized off-the-shelf immunotherapy for prostate cancer.

The non-dilutive grant, titled “Phase 1/2a clinical trial to investigate Bria-PROS+™ in patients with metastatic prostate cancer”, will be used to complete manufacturing of Bria-PROS+ and to fund the upcoming Phase 1/2a study in patients with advanced prostate cancer.

“Despite recent advances in the management of metastatic hormone-sensitive prostate cancer, most patients will progress with significant pain and suffering and limited treatment options,” stated Dr. William Oh, MD, Director of Precision Medicine, Yale Cancer Center, and Principal Investigator on the upcoming Phase 1/2a clinical study of Bria-PROS+ in advanced prostate cancer. “We are grateful to the NCI for recognizing the urgency for this unmet medical need and supporting BriaCell’s breakthrough immunotherapy.”

“This prestigious award will help expedite the clinical development of Bria-PROS+ and is significant validation of our next generation novel personalized immunotherapy approach,” added Dr. William V. Williams, BriaCell’s President and CEO.

“The Bria-OTS+ platform was designed to overcome the complexity, cost and delays of traditional personalized cancer treatments,” noted Miguel Lopez-Lago, PhD, BriaCell’s Chief Scientific Officer. “We believe it will constitute a significant advancement in personalized cancer care.”

About BriaCell Therapeutics Corp.

BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.

Safe Harbor

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include statements regarding the completion of manufacturing of Bria-PROS+; the outcome of the Phase 1/2a clinical trial in metastatic breast cancer; and the ongoing development of Bria-PROS+. These statements are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Investor Relations Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.